Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/15030
Type
ArticleCopyright
Restricted access
Embargo date
2030-01-01
Collections
- IOC - Artigos de Periódicos [12943]
Metadata
Show full item record
ACTIVATION OF TOLL-LIKE RECEPTOR 2 INCREASES MACROPHAGE RESISTANCE TO HIV-1 INFECTION
Author
Affilliation
Montevideo Pasteur Institute. Cell Biology Unit. Montevideo, Uruguay.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Laboratório de Pesquisa Translacional. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Laboratório de Pesquisa Translacional. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Laboratório de Pesquisa Translacional. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Laboratório de Pesquisa Translacional. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil.
Abstract
Patients infected with HIV-1, the etiological agent of AIDS, have increased intestinal permeability, which allows for the passage of microbial products, including Toll-like receptor (TLR) ligands, into circulation. The exposure of HIV-1-infected cells to certain TLR agonists affects viral replication, but studies associating viral production with the activation of TLR2 in HIV-1-infected cells are rare and controversial. Here, we report that the TLR2 ligands Zymosan and Pam3CSK4 potently inhibit HIV-1 replication in acutely infected monocyte-derived macrophages and the exposure to TLR2 ligands prior to infection renders macrophages refractory to HIV-1 production. Macrophage treatment with Pam3CSK4 did not change the cellular expression of the HIV-1 entry receptors CD4 and CCR5. Both TLR2 ligands increased the macrophage production of β-chemokines and IL-10, and the blockage of these soluble factors prevented the inhibitory effect of TLR2 activation on HIV-1 replication. Our findings show that the direct engagement of TLR2 in HIV-1-infected macrophages increase cellular resistance to HIV-1 infection, and that controlling HIV-1 replication with agonists for TLR2 might have implications for the development of antiretroviral therapies.
Share